Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Prestige Brands Q4: The OTC marketer will leverage the success of last season's Chloraseptic liquid center lozenge with the upcoming introduction of a maximum strength lozenge as well as a spray form, according to a May 15 release. In the January-March period, the Irvington, N.Y.-based firm's OTC healthcare business advanced 7 percent to $46.2 million, benefiting from growth of Murine Earigate as well as double-digit growth of Clear Eyes on the launch of Maximum Redness, Prestige Brands reports May 15. Net sales rose 3 percent to $80.4 million and net income grew 24 percent to $10.4 million, the firm notes. For its fiscal year 2008, Prestige Brands' net revenues grew 3 percent to $326.6 million, though net income fell 6 percent to $33.9 million due to a favorable tax benefit in 2007, the firm notes...
You may also be interested in...
People In Brief
FDA's first chief scientist: Frank Torti joins FDA as the agency's chief scientist and principal deputy commissioner, FDA announces April 9. In the newly created position, Torti will help launch the FDA Fellowship Program, an effort to attract as many as 2,000 new professionals to an FDA training program. Despite the absence of congressional funding, the Reagan-Udall Foundation also will be involved in the effort. Torti, whose clinical interests include genitourinary oncology, also will oversee FDA's intramural research programs and emphasize the importance of clinical research trials. He assumes the post in May and is expected to help fill the void in the commissioner's office left by former Chief Medical Officer and Deputy Commissioner Janet Woodcock when she returned to the Center for Drug Evaluation and Research. Torti previously was Director of the Comprehensive Cancer Center at Wake Forest University School of Medicine...
GNC To Be Acquired For $1.65 Bil. By Ares, Ontario Teachers’ Pension Plan
Ares Management and the Ontario Teachers' Pension Plan private investment groups have agreed to purchase the parent company of vitamin and nutritional supplement firm GNC for $1.65 billion, the firms announce Feb. 9
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC